Advances in Treatment of Pulmonary Arterial Hypertension
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20240617.008
- VernacularTitle:动脉型肺动脉高压治疗研究进展
- Author:
Shiwei WANG
1
;
Longli KANG
2
Author Information
1. Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Diseases of Xizang Autonomous Region， School of Medicine， Xizang Minzu University， Xianyang 712082， Shannxi Province， China
2. Key Laboratory of High Altitude Environment and Genes Related to Diseases of Xizang Autonomous Region， School of Medicine， Xizang Minzu University， Xianyang 712082， Shannxi Province， China
- Publication Type:Review
- Keywords:
pulmonary arterial hypertension;
pathogenesis;
molecular mechanism;
vascular remodeling;
medication;
non-drug therapy
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2024;45(4):493-502
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary Arterial Hypertension （PAH） is a chronic progressive cardiopulmonary disease. The main pathological changes are vasoconstriction and pulmonary artery proliferative remodeling and right ventricular hypertrophy. Further exploration of the pathogenesis of PAH can reveal that its related pathways include vascular proliferation， vascular wall remodeling， oxidative stress， inflammatory response and gene regulation. Although great progress has been made in the treatment of PAH in recent years， the mortality rate is still high， current clinical treatments have not effectively improved the prognosis， and the disease has great impact on the physical， social， work and emotional aspects of patients. This article will review the latest research on the treatment of PAH， aiming to provide new clues for the clinical treatment of PAH.
